ArticleJournal of autism and developmental disorders2012
Brief report: Platelet-poor plasma serotonin in autism.
Article in Journal of autism and developmental disorders, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- A Systematic Review on Autism and Hyperserotonemia: State-of-the-Art, Limitations, and Future Directions.Brain sciences · 2024Review
- Blood platelet research in autism spectrum disorders: In search of biomarkers.Research and practice in thrombosis and haemostasis · 2019Review
- RDoC-based categorization of amygdala functions and its implications in autism.Neuroscience and biobehavioral reviews · 2018Review
- Is there sexual dimorphism of hyperserotonemia in autism spectrum disorder?Autism research : official journal of the International Society for Autism Research · 2017Article
- The serotonin system in autism spectrum disorder: From biomarker to animal models.Neuroscience · 2016Review
- Commentary on "Platelet Studies in Autism Spectrum Disorder Patients and First-Degree Relatives".Molecular autism · 2016Article
- Autism biomarkers: challenges, pitfalls and possibilities.Journal of autism and developmental disorders · 2015Review
- A study of blood serotonin and serotonin transporter promoter variant (5-HTTLPR) polymorphism in Egyptian autistic children.Advanced biomedical research · 2015Article
- Association of social and cognitive impairment and biomarkers in autism spectrum disorders.Journal of neuroinflammation · 2014Article
- Examining autism spectrum disorders by biomarkers: example from the oxytocin and serotonin systems.Journal of the American Academy of Child and Adolescent Psychiatry · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Possible explanations for the well-replicated platelet hyperserotonemia of autism include an alteration in the platelet's handling of serotonin (5-hydroxyserotonin, 5-HT) or an increased exposure of the platelet to 5-HT. Measurement of platelet-poor plasma (PPP) levels of 5-HT appears to provide the best available index of in vivo exposure of the platelet to 5-HT. Mean (± SD) concentrations of PPP 5-HT observed in the autism (N = 18), hyperserotonemic subgroup (N = 5) and control (N = 24) groups were 0.86 ± 0.53, 0.87 ± 0.43 and 0.86 ± 0.36 nM, respectively. The results suggest that the hyperserotonemia of autism is not due to increased exposure of the platelet to 5-HT and make it more likely that the factor(s) contributing to the hyperserotonemia of autism have to do with the platelet's handling of 5-HT.
Indexed as
Identifiers
21979109What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.